Search results
Results from the WOW.Com Content Network
The drug accounts for around half of the company's total sales and was one of its main growth drivers last quarter. While most Patent Expirations AbbVie Investors Need to Watch
The original patent, U.S. patent 4,927,855, was granted to Laboratoire L. Lafon in 1990, covering the chemical compound of modafinil. This patent expired in 2010. [224] In 1994, Cephalon filed a patent for modafinil in the form of particles of a defined size, represented by U.S. patent 5,618,845, which expired in 2015. [225]
Modafinil [13] Provigil Nevirapine [citation needed] Norfloxacin [14] Oseltamivir [citation needed] Oxicams [7] Ampiroxicam, Piroxicam, Tenoxicam, Droxicam, Lornoxicam, Meloxicam, Isoxicam: Paracetamol [15] [16] Acetaminophen, Panadol, Tylenol Penicillins [5] Phenytoin [5] Rivoraxaban [17] Xarelto: Sitagliptin [citation needed] Sulfonamides [2 ...
The term patent cliff refers to the phenomenon of patent expiration dates and an abrupt drop in sales that follows for a group of products capturing a high percentage of a market. Usually, these phenomena are noticed when they affect blockbuster products —a blockbuster product in the pharmaceutical industry, for example, is defined as a ...
Bristol-Myers Squibb is facing 2012 patent expirations for two of its three top sellers, Plavix and high blood pressure med Avapro, with global sales in 2010 of $1.2 billion, and its deal to ...
In patent law, the research exemption or safe harbor exemption is an exemption to the rights conferred by patents, which is especially relevant to drugs.According to this exemption, despite the patent rights, performing research and tests for preparing regulatory approval, for instance by the FDA in the United States, does not constitute infringement for a limited term before the end of patent ...
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug ...
The key basis for the rejection was the part of Indian patent law that was created by amendment in 2005, describing the patentability of new uses for known drugs and modifications of known drugs. That section, Paragraph 3d, specified that such inventions are patentable only if "they differ significantly in properties with regard to efficacy."